News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tricida Announces In-House Discovered Clinical Candidate In Cardiorenal Disease



9/4/2014 10:59:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc., a privately-held biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies addressing complications of renal disease, announced today the discovery of a clinical candidate for chronic treatment of complications of cardiorenal disease. Earlier this year, Tricida closed a $10 million Series A financing led by OrbiMed Advisors, with investments by Sibling Capital Ventures and Limulus Venture Partners. Sibling Capital Ventures, Tricida’s founding investor, provided seed funding to enable pre-clinical activities and market validation studies ahead of the Series A financing.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
Tricida
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES